Interview with Murtaza Khorakiwala, Managing Director, Wockhardt
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Address: No. 28, Mehta Vora Chamber, Mahendra Mansion, Babu Genu RoadMumbai – 400 002, Maharashtra, India
Tel: 91 22 26101320
Web: http://www.apexdrugs.com/
Started in 1979 as an Importer for Bulk Drug and API’s, Today Apex Drug House has diversified into manufacturing of pharmaceutical formulations and is at the forefront in developing and marketing for International markets. Our products are manufactured in WHO GMP, NAFDAC, NDA and FDB certified facilities where various forms of pharmaceuticals like Tablets, Capsules, Syrups, Ointments, Lozenges, Dry Powder Injections, Liquid Injections, Ophthalmic solutions and Aerosols are manufactured. Additionally Apex also manufactures Herbals, Soft Gelatin Capsules, Lozenges and specialty products like Mosquito Repellents and Condoms. We focus on providing quality products and continually invest our time and resources in the quest to achieve higher levels of quality products and earned reputation from our clients.
Apex Drug House has a strong presence in regions like Latin America, South East Asia, CIS and African regions. With the know-how and the capacity of our plants we are close to our customers in important markets. We provide a worldwide supply chain, making sure that products will be available when and where they are needed. Our strong portfolio of products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers.
Apex Drug House is a fully integrated pharmaceutical formulation company at the forefront in developing, manufacturing and marketing of formulations for International markets. Additionally Apex also manufactures Herbals, and specialty products like Mosquito Repellents and Condoms. Our strong portfolio of products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world.
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
“India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub.” For Dilip Shah, General…
See our Cookie Privacy Policy Here